Home > Boards > US OTC > Miscellaneous > Kannalife Inc. (KLFE)

Dean14

Combined With 2

Posts 411

Boards Moderated

Alias Born 06/14/18

KLFE

Current Price

Volume:

KLFE Detailed Quote

Current Report Filing (8-k) Edgar (US Regulatory) - 3/18/2020 5: 05: 13 PM

Current Report Filing (8-k) Edgar (US Regulatory) - 1/28/2020 9: 01: 16 AM

Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/3/2019 3: 47: 50 PM

Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 5: 16: 10 PM

Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 8/14/2019 10: 52: 16 AM

Quarterly Report (10-q) Edgar (US Regulatory) - 8/13/2019 12: 48: 10 PM

Notice of Effectiveness (outcome) Edgar (US Regulatory) - 8/13/2019 6: 00: 43 AM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 8/8/2019 2: 07: 28 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 7/30/2019 11: 19: 33 AM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 7/5/2019 12: 18: 40 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 6/17/2019 1: 54: 14 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 5/23/2019 2: 53: 01 PM

Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2019 2: 13: 44 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 4/9/2019 1: 52: 41 PM

Annual Report (10-k) Edgar (US Regulatory) - 4/9/2019 1: 49: 06 PM

Notification That Annual Report Shall Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 4/1/2019 3: 54: 58 PM

Dean14 Thursday, 01/23/20 09: 10: 12 AM

Re: None

Post # of 34

Medical Marijuana, Inc. Portfolio fundamental stock investment (click through the following post) Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents

9: 00 AM ET 1/23/20 | Dow Jones

The San Diego Area, Jan. 23, 2020 /PRNewswire/ – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-at any time publicly dealt cannabis corporation in the states that unveiled the world's very first-ever before cannabis-extracted nutraceutical products and solutions, brands and supply chain, introduced these days that its profile expense provider Kannalife, Inc. (“Kannalife”) (OTC: KLFE) just lately furnished an upgrade on its intellectual residence rotating close to its international WIPO/PCT Patent WO2015/106108A2 known as “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the management of Hepatic Encephalopathy” (the “PCT Patent”).

“Our company is very proud to get Kannalife as a part of our financial investment account because they are continually getting to new milestones in studying cannabinoid therapeutics,” reported Medical Marijuana, Inc. CEO Dr. Stuart Titus. “The quantity of study during this room has increased significantly within the last year or so however, there is even now major advance to generally be created. It's stimulating to determine Kannalife the main thing on this.”

Considering that the processing from the PCT Patent in 2015, Kannalife has brought patent approval in the adhering to areas: U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and also their Approach to Use for managing Hepatic Encephalopathy,” U.S. Patent 10,004,722 “Technique for dealing with hepatic encephalopathy or simply a disease connected to cost-free major mediate stress and anxiety and oxidative pressure with creative functionalized 1,3-benzene diols,” Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols together with their Way of Use for managing Hepatic Encephalopathy” and Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols in addition to their Technique of Use for treating Hepatic Encephalopathy.”

Additionally, Kannalife's application form for patent defense of their mental home is well-accepted in the European Union (EU), China, and Australia. This Company is awaiting notice from India, Brazil and Canada for observe of acceptance. The Firm anticipates invoice of patent grants or loans in the The far east, Modern australia and EU a while while in the very first and second quarters of 2020.

“If we submitted our patent program for 'Novel Functionalized 1,3-Benzene Diols together with their Method of Use for managing Hepatic Encephalopathy,' we picked what we think to become essentially the most feasible pharmaceutical trading markets for transferring our compounds into numerous studies,” reported Dean Petkanas, CEO of Kannalife. “An added patents we now have received will help us accomplish the targets in further markets.”

Currently, Kannalife's primary substance selection KLS-13019, a cannabidiol (CBD)-like molecule is going to be researched in pre-scientific tests for any possibilities management of neuropathic agony. Through in depth evaluation, Kannalife has identified a potent, non-opioid alternative to the frontline treatments for radiation treatment-induced peripheral neuropathy (CIPN).

About Medical Marijuana, Inc.

We have been a corporation of firsts. Medical Marijuana, Inc. (MJNA) is often a cannabis provider with a few distinctive company items during the non-psychoactive cannabinoid room: a worldwide profile of cannabinoid-centered nutraceutical brand names driven by Kannaway and HempMeds a pioneer in finding the highest-good quality authorized non-psychoactive marijuana products derived from industrial hemp as well as a cannabinoid-primarily based specialized medical investigation and botanical drug advancement sector directed by its inner R&D and technological crew and its drug investment decision corporations and spouses which include AXIM Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was given its name a top CBD maker by CNBC. Medical Marijuana, Inc. seemed to be the very first organization to acquire ancient import makes it possible for for CBD goods in the nations of Brazil,Mexico and Argentina, and Paraguay as well as being a leader in the growth of intercontinental market segments. Medical Marijuana, Inc.'s headquarters is set in San Diego County, California, and other info is offered at OTCMarkets.com or at www.medicalmarijuanainc.com.

To discover Medical Marijuana, Inc.'s corporation movie, click the link.

About KLS-13019

KLS-13019 is Kannalife's main exclusive investigational CBD-like product or service to the possibilities treating a range of neurodegenerative and neuropathic pain conditions, starting with chemo-induced peripheral neuropathy (CIPN). KLS-13019 is not examined or authorised for affected individual use by the U.S. Food and Drug Administration (FDA) or another medical care authority across the world. Its security and efficacy have not been affirmed by FDA-approved analysis.

About Kannalife, Inc.

Family Office - A.D. Financial Sdn. Bhd.www.adfinancial.com.my › services › family-office A family office is dedicated to providing families with centralised support in managing their wealth to enable it to endure over several generations. What is a Family …

Kannalife, Inc. is usually a biopharmaceutical organization focused entirely on the roll-out of amazing and branded cannabidiol (CBD) and CBD-like molecules for individuals troubled with unmet health requirements of neurodegenerative conditions - which includes radiation treatment-stimulated peripheral neuropathy (CIPN), a chronic neuropathy attributable to dangerous chemotherapeutic agencies hepatic encephalopathy (HE), a neurotoxic mental faculties-liver organ disorder brought on by substantial levels of ammonia and ethanol inside the human brain minor traumatic head damage (mTBI), a illness connected to single and repeating impression traumas and persistent stressful encephalopathy (CTE) a sickness connected with really recurring effect injury in specialist and inexperienced sports activities.

The Company's group of proprietary molecules is focused on curing oxidative stress and anxiety-linked conditions like HE, constant suffering from neuropathies like CIPN, and neurodegenerative ailments like CTE. Kannalife conducts its growth and researching attempts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

FORWARD-LOOKING DISCLAIMER

(Image: https://burst.shopifycdn.com/photos/child-with-i-love-mom-sign.jpg?width=746&format=pjpg&exif=0&iptc=0)This mass media release could have specified ahead-shopping records and data, as outlined around the meaning of Section 27A with the Securities Act of 1933 and Section 21E of your Securities Exchange Act of 1934, and is be subject to the Safe Harbor produced by these portions. This product features phrases about estimated long term functions and/or monetary benefits that will be onward-searching in character and issue to uncertainties and potential risks. Such in front-looking statements obviously include other, uncertainties and risks things, that may cause the exact benefits, performance or accomplishments of Medical Marijuana, Inc. to generally be materially different from the statements produced herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been looked at through the Food and Drug Administration. This device is not created to heal, establish and take care of or protect against any condition.